Your browser is no longer supported. Please, upgrade your browser.
Synthetic Biologics, Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own0.10% Shs Outstand132.04M Perf Week-6.19%
Market Cap55.39M Forward P/E- EPS next Y-0.11 Insider Trans60.94% Shs Float129.71M Perf Month-14.42%
Income-20.50M PEG- EPS next Q-0.03 Inst Own5.00% Short Float0.01% Perf Quarter-18.00%
Sales- P/S- EPS this Y32.50% Inst Trans- Short Ratio0.01 Perf Half Y-31.23%
Book/sh0.58 P/B0.72 EPS next Y15.40% ROA-47.40% Target Price1.88 Perf Year28.29%
Cash/sh0.56 P/C0.75 EPS next 5Y- ROE-58.20% 52W Range0.28 - 1.70 Perf YTD9.53%
Dividend- P/FCF- EPS past 5Y48.90% ROI- 52W High-75.32% Beta1.75
Dividend %- Quick Ratio36.00 Sales past 5Y- Gross Margin- 52W Low48.08% ATR0.02
Employees10 Current Ratio36.00 Sales Q/Q- Oper. Margin- RSI (14)40.44 Volatility5.95% 5.04%
OptionableNo Debt/Eq0.00 EPS Q/Q86.60% Profit Margin- Rel Volume0.85 Prev Close0.41
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume1.49M Price0.42
Recom2.00 SMA20-3.66% SMA50-8.78% SMA200-30.04% Volume1,268,067 Change1.85%
Jan-06-17Reiterated FBR & Co. Outperform $5 → $6
May-06-16Reiterated FBR Capital Outperform $10 → $9
Feb-26-16Initiated FBR Capital Outperform $10
Oct-13-15Initiated RBC Capital Mkts Outperform $8
Mar-16-15Downgrade Maxim Group Buy → Hold $3
Mar-02-15Reiterated Maxim Group Buy $6 → $3
Mar-19-14Reiterated Maxim Group Buy $3 → $6
Sep-30-13Initiated Maxim Group Buy $3
Jun-25-13Initiated Ascendiant Capital Markets Buy $2.25
Oct-26-21 07:00AM  
Oct-21-21 07:00AM  
Oct-06-21 04:30PM  
Sep-21-21 04:30PM  
Sep-10-21 12:19PM  
Aug-05-21 04:10PM  
Aug-03-21 07:00AM  
Jul-28-21 07:00AM  
Jun-29-21 07:00AM  
Jun-14-21 03:35PM  
May-26-21 07:00AM  
May-05-21 04:10PM  
Apr-28-21 07:00AM  
Apr-14-21 07:00AM  
Apr-01-21 07:00AM  
Mar-04-21 04:10PM  
Feb-04-21 05:38AM  
Dec-22-20 07:00AM  
Nov-24-20 07:00AM  
Nov-16-20 07:00AM  
Nov-12-20 07:00AM  
Nov-10-20 04:15PM  
Nov-03-20 04:30PM  
Oct-02-20 07:00AM  
Jun-30-20 07:00AM  
Jun-15-20 11:41AM  
May-27-20 07:00AM  
May-13-20 12:20PM  
May-06-20 09:55AM  
May-05-20 04:15PM  
Apr-28-20 04:30PM  
Mar-16-20 03:41PM  
Feb-26-20 12:29PM  
Feb-23-20 02:26PM  
Feb-20-20 04:15PM  
Feb-07-20 04:30PM  
Feb-06-20 01:53PM  
Jan-07-20 07:00AM  
Dec-30-19 05:54AM  
Dec-24-19 07:29AM  
Nov-30-19 09:39AM  
Nov-27-19 04:30PM  
Nov-21-19 12:21AM  
Nov-14-19 11:23AM  
Nov-06-19 12:02PM  
Nov-04-19 04:10PM  
Oct-28-19 04:30PM  
Sep-26-19 07:00AM  
Sep-06-19 11:24AM  
Sep-01-19 10:50PM  
Aug-28-19 01:12PM  
Aug-20-19 09:46AM  
Aug-08-19 04:15PM  
Aug-01-19 07:00AM  
Jul-01-19 07:00AM  
May-27-19 03:14PM  
May-24-19 10:25AM  
May-22-19 12:55PM  
May-08-19 06:02PM  
Apr-30-19 04:30PM  
Apr-20-19 03:38AM  
Feb-27-19 04:10PM  
Feb-26-19 10:38AM  
Feb-19-19 04:30PM  
Jan-03-19 07:00AM  
Dec-18-18 10:38AM  
Dec-04-18 12:00PM  
Nov-27-18 08:20AM  
Nov-22-18 09:10AM  
Nov-21-18 09:25AM  
Nov-08-18 06:02PM  
Oct-30-18 04:30PM  
Oct-18-18 08:40AM  
Oct-15-18 01:30PM  
Oct-12-18 07:35AM  
Oct-11-18 09:07AM  
Sep-30-18 09:26AM  
Sep-06-18 07:00AM  
Aug-30-18 04:10PM  
Aug-23-18 09:50PM  
Aug-17-18 02:32PM  
Aug-13-18 07:55AM  
Aug-08-18 05:31PM  
Aug-01-18 05:05PM  
Jul-31-18 07:00AM  
Jun-20-18 07:50AM  
May-22-18 07:00AM  
May-21-18 07:25AM  
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHALLCROSS STEVEN ACEO and CFOMay 10Buy0.4950,00024,595100,000May 10 05:30 PM